Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- The UK Approves Amgen’s (AMGN) Tarlatamab to Treat Small Cell Lung Cancer
- Historical Trends Warrant a Closer Look at Novo Nordisk (NVO) Call Options
- Bristol-Myers Squibb’s Patent Expansion Plan May Run into Regulator Trouble
- Why Elon Musk Prefers Eli Lilly’s (LLY) Mounjaro over Novo Nordisk’s Ozempic
- Biotech Alert: Searches spiking for these stocks today